Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News

Icon

Pending FDA review and approval, research findings pave way for Akili’s EVO to become first brain training platform prescribed for ADHD

Akili Achieves Pri­ma­ry Effi­ca­cy End­point in ADHD Tri­al (MD mag­a­zine):

Boston-based Akili Inter­ac­tive has announced top-line results from the STARS-ADHD piv­otal study of its inves­ti­ga­tion­al dig­i­tal ther­a­peu­tic med­i­cine AKL-T01, in treat­ment of pedi­atric atten­tion-deficit/hy­per­ac­tiv­i­ty dis­or­der (ADHD)…The dig­i­tal med­i­cine, AKL-T01, is a video game for patients to play on tablet devices. It uses the same sto­ry­telling and reward mech­a­nisms as stan­dard videogames; how­ev­er, it fea­tures mech­a­nisms to act on neur­al sys­tems and algo­rithms that dial the lev­el of stim­u­lus up or down, meet­ing the needs of the patient.

In the STARS-ADHD ran­dom­ized, con­trolled tri­al of 348 chil­dren and ado­les­cents diag­nosed with ADHD, AKL-T01 showed a sta­t­i­cal­ly sig­nif­i­cant improve­ment com­pared to an active con­trol group on the pre­de­fined pri­ma­ry end­point, a change in the Atten­tion Per­for­mance Index (API), a com­pos­ite score from the Test of Vari­ables of Atten­tion (TOVA)…

After the 4-week peri­od, an assess­ment mea­sured changes from base­line on stan­dard mea­sures of atten­tion, mem­o­ry and impul­siv­i­ty. Chil­dren and ado­les­cents that received AKL-T01 showed a sta­tis­ti­cal­ly mean­ing­ful improve­ment in atten­tion­al func­tion­ing on the API…Engineered as a ther­a­peu­tic active treat­ment for cog­ni­tive defi­cien­cy, AKL-T01 is built on Akili’s patent­ed Project: EVO tech­nol­o­gy plat­form that allows selec­tive tar­get­ing and acti­va­tion of spe­cif­ic cog­ni­tive neur­al sys­tems in the brain that exhib­it defi­cien­cy from var­i­ous med­ical con­di­tions…

Akili plans to file for reg­u­la­to­ry approval with the US Food and Drug Admin­is­tra­tion in the first half of 2018 for clear­ance as a nov­el treat­ment for chil­dren and ado­les­cents with ADHD, paving the way for the first ‘dig­i­tal’ pre­scrip­tion prod­uct to direct­ly treat a dis­or­der.

The com­pa­ny is also study­ing whether a sim­i­lar ver­sion of its video game could poten­tial­ly treat adults with depres­sion, and the Akili recent­ly start­ed a mid-stage clin­i­cal tri­al with ear­ly results expect­ed late next year.”

The Study (ongoing)

Soft­ware Treat­ment for Active­ly Reduc­ing Sever­i­ty of ADHD (STARS-ADHD) (ClinicalTrials.gov)

  • Pur­pose: The pur­pose of this study is to eval­u­ate the effects of videogame-like dig­i­tal ther­a­pies on atten­tion­al func­tion­ing and symp­toms in chil­dren diag­nosed with ADHD.
  • Offi­cial title: A Ran­dom­ized, Con­trolled, Par­al­lel-group, Inter­ven­tion Study to Assess At-home, Game-based Dig­i­tal Ther­a­py for Treat­ing Pedi­atric Par­tic­i­pants Ages 8 to 12 Years Old With Atten­tion Deficit Hyper­ac­tiv­i­ty Dis­or­der (ADHD)
  • Detailed descrip­tion: The study will be a ran­dom­ized, par­al­lel group, con­trolled tri­al of two videogame-like (iPad-based) dig­i­tal ther­a­pies. The study will con­sist of 3 pri­ma­ry phas­es: Screen­ing, Washout/Baseline, and Treat­ment. Dur­ing the Screen­ing Phase (Day -28 to Day -7), par­tic­i­pants will under­go screen­ing to eval­u­ate eli­gi­bil­i­ty for the study. Screen­ing may take place up to 28 days before the Base­line Vis­it (Day 0). For those chil­dren cur­rent­ly on med­ica­tion for ADHD the Washout peri­od will begin 7 days pri­or to Base­line where treat­ment will be dis­con­tin­ued. On Day 0, the Base­line vis­it will occur where­in addi­tion­al eli­gi­bil­i­ty cri­te­ria will be estab­lished. The Treat­ment Phase (Day 1 to Day 27) will involve using the dig­i­tal ther­a­py at home for each par­tic­i­pant fol­lowed by an In-Clin­ic assess­ment on Day 28 to assess key out­comes. Com­pli­ance with treatment/use require­ments will be mon­i­tored remote­ly dur­ing this phase.
  • Just announced top-line results: HERE

The Study in Context

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Attention and ADD/ADHD, Cognitive Neuroscience, Health & Wellness, Technology

Tags: , , , , , , , , , , , , , ,